Provided by Tiger Fintech (Singapore) Pte. Ltd.

Charles River Laboratories

166.63
-8.4900-4.85%
Post-market: 165.50-1.1300-0.68%18:22 EDT
Volume:1.21M
Turnover:203.88M
Market Cap:8.52B
PE:833.15
High:175.07
Open:173.14
Low:165.67
Close:175.12
Loading ...

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Business Wire
·
16 Jan

Evercore ISI Sticks to Their Hold Rating for Charles River Labs (CRL)

TIPRANKS
·
16 Jan

Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
16 Jan

Baird Adjusts Price Target on Charles River Laboratories International to $177 From $197, Keeps Neutral Rating

MT Newswires Live
·
15 Jan

Charles River Laboratories International Inc : Baird Cuts Target Price to $177 From $197

THOMSON REUTERS
·
15 Jan

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EST

Reuters
·
15 Jan

Top Stock Movers Now: United Rentals, KB Home, Eli Lilly, and More

Investopedia
·
15 Jan

Charles River Laboratories Stock Falls 6% on Dim FY25 Outlook

Dow Jones
·
15 Jan

Charles River Laboratories Shares Down 3.7% After Co Expects 2025 REV to Decline in a Similar Range as Estimated in 2024

THOMSON REUTERS
·
14 Jan

BUZZ-Charles River Lab falls after company's 2025 revenue forecast

Reuters
·
14 Jan

Charles River Laboratories Shares Extend Losses, NOW Down 11.4% Premarket

THOMSON REUTERS
·
14 Jan

BRIEF-Charles River Laboratories International Expect 2025 Revenue Will Decline Organically In A Similar Range As Estimated In 2024

Reuters
·
14 Jan

Charles River Laboratories Shares Down 6.4% Premarket After Co Expects 2025 REV to Decline in a Similar Range as Estimated in 2024

THOMSON REUTERS
·
14 Jan

Charles River Laboratories International Inc: Expect 2025 Non-Gaap Operating Margin Will Be Modestly Below Estimated 2024 Level

THOMSON REUTERS
·
14 Jan

Charles River Laboratories : Ongoing Site Consolidation Actions Will Result in a Revenue Headwind of About 0.5% in 2025

THOMSON REUTERS
·
14 Jan

Charles River Laboratories : Lower Commercial CDMO Revenue Expected to Reduce Consolidated Revenue Growth by About 1% in 2025

THOMSON REUTERS
·
14 Jan